Corporate healthcare policies are based on real world figures and estimates based on actions taken from previous fiscal years, e.g. mass vaccinations. It is estimated that more than 1.7 million new cancer cases are expected to be diagnosed in 2019 (Table 1), according to the data published by the American Cancer Society this year.
This estimate, according to the same report, does not include carcinoma in situ (noninvasive cancer) of any site except urinary bladder, nor does it include basal cell or squamous cell skin cancers because these are not required to be reported to cancer registries. In short, there will be more than they could feast upon as the days go by.
Table 2 provides estimated new cancer cases in 2019 by state.
How many will die of cancer this year?
About 606,880 Americans are expected to die of cancer in 2019 (Table 1), which translates to about 1,660 deaths per day.
Cancer is the second most common cause of death in the US, exceeded only by heart disease. Table 3 provides estimated cancer deaths by state in 2019.
All of these figures can help in the determination of pricing of medical goods and services, and the exact amount of investments in the building of new hospitals and morgues across the different states. The rest will be budgeted for public relations and medical incentives for all professional medical practitioners who are devoutly participating in the real world hunger games.
As of today, the top 6 pharmaceutical stocks that you can buy shares from are the following:
- Eli Lilly & Co. (LLY)
- Market Cap: $124.73 billion
- Performance: 35.6% annual return
- Merck & Co., Inc. (MRK)
- Market Cap: $196.84 billion
- Performance: 34.5% annual return
- Pfizer Inc. (PFE)
- Market Cap: $227.87 billion
- Performance:18.7% annual return
- Zoetis Inc. (ZTS)
- Market Cap: $48.98 billion
- Performance: 17.7% annual return
- Johnson & Johnson (JNJ)
- Market Cap: $375.67 billion
- Performance: -7.3% annual return
- AbbVie Inc. (ABBV)
- Market Cap: $116.53 billion
- Performance: -9.33% annual return
According to its published company profile, The Indianapolis, Indiana-based Eli Lilly is a global pharmaceutical company with a 142-year-long record in researching, creating, and marketing high-quality medicines. With offices in 18 different countries and business operations spanning more than 125 countries across the globe, the company operates through four dedicated business segments – oncology, bio-medicines, diabetes, and international.
Eli Lilly is where Dr. John Rengen Virapen used to work for the better part of his life. It was the birth of his own son that changed it all.
“I worked in an industry, the Pharmaceutical Industry that do nothing, but annihilate the population of this word. They kill more people than wars we have in the world, but long term. They punish you and then they kill you.” – Dr. John R. Virapen
Whether one dies or cured of cancer, both scenarios are always unwelcomed. The primary objective is to prolong the agony, as much as possible, which explains the contradicting prescriptions of hazardous chemo, sodium bicarbonate, and a load of multi-vitamins.
According to a peer-reviewed study, a majority of patients (51.3%) received conflicting medication information that had a direct negative effect on medication adherence. Experts, as they claimed they are, medical practice is a very stressful profession of endless conflict between conscience and the insatiable desire for material wealth.
Cancer takes about 10 years to develop from the time of infection, whether induced or consequential. The 10-year leadtime is a strong manifestation of the resiliency and competence of the autoimmune system without any form of intervention.
If each of the estimated 1.7 million new cancer cases spends $250,000 for cancer treatment, a whopping $425 billion can be generated in the US alone. But this estimate is too conservative considering that in the year 2017 alone, the U.S. health care spending grew by 3.9 percent, reaching $3.5 trillion or $10,739 per person.
That is, of course, a combined figure of expenditures for all types of health conditions from The National Health Expenditure Accounts (NHEA).
Globally, the total health expenditures in 2015 alone is pegged at $7.2 trillion. About half of that amount was spent by the Americans, which makes them the most chemically and financially devastated population on the planet.
All of the above numbers continue to feed the corrosive system in spite of the growing number of independent companies promoting alternative approaches to healthcare.
Imagine if, instead of poisoning ourselves with toxic chemicals that have no useful purpose in our body, we spent the $7.2 trillion on the implementation of better technologies, new infrastructures, housing and new industries, we could have dotted this planet with beautiful, sustainable cities and better societies, a long time ago.
But we always make it a point that we are not in full control of ourselves and our government. So, when do we start doing exactly that? When do we stop thinking that we are weak and powerless?
We still have a long way to go, indeed.